AD-303A: Topical AD-303A applied to the scalp according to the study protocol.
AD-3031: Oral AD-3031 administered according to the study protocol.
Study summary
This is a randomized, open-label phase 1/2a study designed to evaluate the pharmacokinetics, pharmacodynamics, and safety of AD-303A (topical formulation) and AD-3031 in male patients with androgenetic alopecia. The study aims to compare pharmacological characteristics and safety profiles to support dose selection for further clinical development.
Eligibility
Sex
MALE
Min age
19 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Male participants aged 19 to 55 years.
* Clinical diagnosis of androgenetic alopecia.
* Healthy as determined by medical history, physical examination, vital signs, electrocardiogram (ECG), and clinical laboratory tests.
* Willing and able to comply with all study procedures and visit schedules.
Exclusion Criteria:
* History or presence of dermatologic conditions affecting the scalp other than androgenetic alopecia.
* Prior hair transplantation or scalp surgery that may affect evaluation of hair growth.
* Use of medications known to affect hair growth (e.g., finasteride, dutasteride, minoxidil) within 6 months prior to screening.
Primary outcome measure(s)
Maximum observed plasma concentration (Cmax) of dutasteride — Up to Day14 The maximum observed plasma concentration (Cmax) of dutasteride following administration of the study drug.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.